MacroGenics Inc (NASDAQ:MGNX) – Analysts at SunTrust Banks issued their FY2022 earnings per share (EPS) estimates for shares of MacroGenics in a research note issued to investors on Thursday. SunTrust Banks analyst P. Lawson expects that the biopharmaceutical company will post earnings per share of ($1.39) for the year.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $5.50 million. MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The business’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.97) earnings per share.

MGNX has been the topic of several other research reports. BidaskClub upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a report on Friday, January 5th. Zacks Investment Research upgraded shares of MacroGenics from a “sell” rating to a “hold” rating in a report on Thursday, January 11th. ValuEngine upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Cowen restated a “buy” rating on shares of MacroGenics in a report on Wednesday, October 25th. Finally, Raymond James Financial restated a “buy” rating on shares of MacroGenics in a report on Monday, December 11th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $30.10.

Shares of MacroGenics (MGNX) traded up $0.30 during trading on Monday, reaching $19.19. 259,900 shares of the company’s stock were exchanged, compared to its average volume of 196,500. The company has a market capitalization of $706.63, a P/E ratio of -4.27 and a beta of 2.73. MacroGenics has a fifty-two week low of $14.36 and a fifty-two week high of $22.31.

In other news, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the transaction, the senior vice president now owns 35,000 shares in the company, valued at $700,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 20,000 shares of company stock worth $400,000. Corporate insiders own 8.30% of the company’s stock.

Large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new position in MacroGenics in the 2nd quarter worth approximately $133,000. Legal & General Group Plc increased its holdings in MacroGenics by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 328 shares during the period. Parametric Portfolio Associates LLC acquired a new position in MacroGenics in the 2nd quarter worth approximately $203,000. Virtu KCG Holdings LLC acquired a new position in MacroGenics in the 2nd quarter worth approximately $232,000. Finally, Citigroup Inc. increased its holdings in MacroGenics by 8.4% in the 2nd quarter. Citigroup Inc. now owns 18,975 shares of the biopharmaceutical company’s stock worth $332,000 after buying an additional 1,466 shares during the period. Institutional investors own 85.78% of the company’s stock.

WARNING: “MacroGenics Inc Forecasted to Earn FY2022 Earnings of ($1.39) Per Share (MGNX)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2018/01/22/macrogenics-inc-forecasted-to-earn-fy2022-earnings-of-1-39-per-share-mgnx.html.

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.